Diagnostics chain: clinical labs, patient centres and pick-up points across India, Nepal and Bangladesh.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 83 | 83 | 83 | 83 | 83 | 84 | 84 | 168 |
| Reserves | 933 | 1.1k | 1.4k | 1.6k | 1.7k | 2.1k | 2.3k | 2.3k |
| Borrowings | 0 | 0 | 385 | 281 | 142 | 151 | 156 | 193 |
| Other Liabilities | 302 | 356 | 354 | 350 | 406 | 336 | 415 | 383 |
| Total Liabilities | 1.3k | 1.6k | 2.2k | 2.3k | 2.3k | 2.6k | 3.0k | 3.0k |
| AssetsFixed Assets | 297 | 300 | 371 | 361 | 1.1k | 1.1k | 1.2k | 1.1k |
| CWIP | 11 | 9 | 14 | 5 | 6 | 3 | 17 | 7 |
| Investments | 253 | 171 | 1.1k | 1.2k | 213 | 416 | 486 | 513 |
| Other Assets | 757 | 1.1k | 764 | 740 | 1.0k | 1.2k | 1.2k | 1.4k |
| Total Assets | 1.3k | 1.6k | 2.2k | 2.3k | 2.3k | 2.6k | 3.0k | 3.0k |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (99.6×) and current (50.3×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 25.8% growth and a 50× exit, ₹1636 only delivers your return if you pay ₹2,365. The price is currently baking in 18% growth.
EPS grows 25.8%/yr for 5 years, then fades to 6% over 2, exits at 50×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 25.8% | 40.90 |
| FY28 | 25.8% | 51.45 |
| FY29 | 25.8% | 64.72 |
| FY30 | 25.8% | 81.42 |
| FY31 | 25.8% | 102.43 |
| FY32 | 15.9% ·fade | 118.71 |
| FY33 | 6.0% ·fade | 125.84 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.